drugset
drugset / Trial / NCT00550303

Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens

NCT00550303 ↗

Phase 1 Completed 28 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedCrossoverOpen-labelTreatment

Summary

The primary purpose is to determine bioavailability of Bazedoxifene/conjugated estrogen formulations for future testing purposes.

Timeline

Start
2007-10
Primary completion
—
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified — —
Subject conjugated estrogens Other / unclassified — —

Indications

No indication recorded.